BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 23,600 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.


Contact Details:
Novo Allé
Bagsværd
2880
Denmark
Tel:+45 4444 8888
Fax:+45 4449 0555
Email:
WWW:

www.novonordisk.com/




Recent Publications by Novo Nordisk:

Evaluation of the injection force dynamics of a modified prefilled insulin pen.
OBJECTIVE: A modified version of the widely used pen FlexPen (FP), called...
20th August, 2008
Novo Nordisk A/S, Brennum Park, DK-3400 Hillerod, Denmark. Expert Opin Pharmacother. 2008 Sep;9(13):2217-22.
DOI Direct Link
Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor.
The crystal structure of the complex between an N-terminally truncated...
20th August, 2008
Protein Engineering, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Malov, J Biol Chem. 2008 Jul 4;283(27):19085-94. Epub 2008 May 8.
DOI Direct Link
Association Between Disability Measures and Short-term Health Care Costs Following Intracerebral Hemorrhage.
BACKGROUND AND PURPOSE: Small improvements in clinical outcomes after...
13th August, 2008
Global Development, Novo Nordisk A/S, Krogshojvej 55, 2880, Bagsvaerd, Neurocrit Care. 2008 Aug 12.
DOI Direct Link
Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VLLa by glycosidase digestions, liquid chromatography, and mass spectrometry.
The two asparagine-linked glycosylation sites of recombinant coagulation...
13th August, 2008
Department of Protein Chemistry Ge, Novo Nordisk A/S, Niels Steensensvej Mol Biotechnol. 1998 Jun;9(3):195-204.
DOI Direct Link
In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
BACKGROUND: Recombinant activated factor VII (rFVIIa) is indicated to...
12th August, 2008
Pharmaceutics, Biopharm, Novo Nordisk A/S, Novo Alle, Bagsvaerd, Denmark. Clin Ther. 2008 Jul;30(7):1309-15.

View more Novo Nordisk research publications.

BioNews Results for Novo Nordisk:

Novo-Nordisk downgraded to 'underperform'
New Ratings:  Aug 29 2008 5:33PM Matching: novo nordisk
Advances in Glucagon-like Peptides for the Treatment of Type 2 Diabetes
Medscape:  Aug 29 2008 8:21PM Matching: novo nordisk
Bernstein Downgrades Novo Nordisk (NVO) to Underperform
Street Insider:  Aug 29 2008 12:47PM Matching: novo nordisk
New Novolog Mix Strength Approved
Facts & Comparisons:  Aug 29 2008 6:41PM Matching: novo nordisk
www.companiesandmarkets.com: Novo Nordisk AS - SWOT Analysis
Macro World Investor:  Aug 28 2008 3:03PM Matching: novo nordisk
Promote your company here: BioNewsCast - Press Release Distribution

View more Novo Nordisk news.

Novo Nordisk Patents:

US Patent No.Title
7078479 Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
7176288 Human coagulation factor VII variants
7186721 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines
7192768 Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro
7192952 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV

View more Novo Nordisk patents.

Novo Nordisk (NVO) Financial information Links from Barchart

NVO Quote from from Barchart.com
NVO Chart from from Barchart.com
NVO Profile from from Barchart.com
NVO Opinion from from Barchart.com

View more Novo Nordisk finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 258 individuals from Novo Nordisk using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 377 times since April 2007, the link to the organisation's website has been followed 44 times

Recent Search Terms used to find this page: novo | silac | contacts at novo nordisk canada human resources | novo nordisk country managing director uk | novonordisk mumbai address | novonordisk mumbai address | Novo All 2880 Bagsv rd map | novo nordisk protein copenhagen malov | novo nordisk zurich | Novo Nordisk mumbai contact details | .

Search for more companies in Bagsværd

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Novo Nordisk
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.